Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Q1 2023 Earnings Presentation
14 slides from Celon Pharma Sa's earnings presentation, May 25, 2023
Slide 1: Investor Presentation 1Q2023 results
INVESTOR PRESENTATION 1Q2023 results WARSAW // 25.05.2023
Slide 2: Disclaimer
Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein is being is
Slide 3: Pharma Financials
PHARMA FINANCIALS
Slide 4: Segment dynamics - 1Q23 vs 1Q22
Segment dynamics - FY 2021/2022 Well balanced business model with growing R&D costs INNOVATIVE PRODUCTS (R&D) TOTAL BRANDED GENERICS R&D . Revenues Revenues Revenues 39,3 43,9 41,9 8,7 4,6 33,3 1Q23 1Q22 1Q23 1Q22 1Q23 1Q22 Expenses Expenses Expenses 57,8 30,1 27,7 53,1 27,5 25,6 1Q23 1Q22 1Q23 1Q22
Slide 5: Group and Segment P&L Details
Group and Segment P&L Details. Branded generics segment Innovation segment Total PLN million 1Q23 1Q22 1Q23 1Q22 1Q23 1Q22 Revenues from sales of medicines 39,0 32,9 0,0 0,0 39,0 32,9 Other revenues 0,3 0,3 0,0 0,0 0,3 0,3 Revenues from grants 0,0 0,0 4,6 8,7 4,6 8,7 Revenues from sales of licences
Slide 6: Balance sheet
Balance sheet. PLN mln 2023-03-31 2022-12-31 ASSETS 618,1 642,4 A. Increase in property, plant and equipment as at 31Mar23 compared to Non-current assets 408,9 404,8 Property, plant and equipment A 308,0 306,8 31Dec22 is related to intense CAPEX that the Company has been Right-of-use assets A 39,5 3
Slide 7: Pharma Branded Generics
PHARMA BRANDED GENERICS
Slide 8: Revenues Q12022-Q12023
Revenues Q12022-Q12023 100 +4,3 -4.1 +1,8 39,3 33,3 (MLN PLN) 0 Domestic Export Grants Q12022 sales Q12022
Slide 9: Robust market position of key promoted products in Poland
Roboust market position of key promoted products in Poland Q12022/Q12023 18% Q12022 Q12023 16% 14% 12% 10% Q12022 Q12023 8% Q12022 Q12023 6% 4% Q12022 Q12023 2% 0% Salmex Ketrel Valzek Donepex
Slide 10: Countries driving export sales in Q12023
Countries driving export sales in Q12023 2 500 Total 2 305 2 000 1 500 1 000 Finland/ Sweden Norway 563 Germany Italy 500 387 361 Austria Czech Rep 347 /Slovakia 264 258 125 Others ( 000’ EUR) 0 1
Slide 11: Pharma Innovative Business
PHARMA ININIOW NENA BUSINESS
Slide 12: News flow & key milestones 2023/2024
News flow & key milestones 2023/2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 CPL’280 end of Phase 2 in diabates CPL’36 end of Phase 2 in both indications CPL’116 end of Phase 2 in RA CPL’116 CPL’280 end of Phase 2 in RA start of Phase 2b in diabetes CPL’280 start of Phase 2 in diabetes Metabolic dis
Slide 13: Partnering strategy 2023/2024
Partnering strategy 2023/2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 FALKIERI CPL’ 280 CPL’36 CPL’116 CPL’110 Metabolic diseases Oncology Neuropsychiatry Inflamatory diseases
Slide 14: Q&A
QA